Diabetes and Glucose Management in People on Hemodialysis.

Q3 Medicine

Diabetes Spectrum Pub Date : 2025-02-14 eCollection Date: 2025-01-01 DOI:10.2337/dsi24-0015

Shubham Agarwal, Julia K Mader, Giuliana Arevalo, Sreekant Avula, Efren Chavez, Lance A Sloan, Rodolfo J Galindo

引用次数: 0

Abstract

Diabetes is a major cause of end-stage kidney disease (ESKD). Glycemic management is challenging in this population, and A1C, commonly used for monitoring glycemic control, is unreliable. Continuous glucose monitoring indices can be used for glycemic monitoring in people with ESKD. Dipeptidyl peptidase 4 inhibitors, incretin mimetic agents (glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptor agonists), and insulin using an automated insulin delivery system are preferred to manage diabetes in people with ESKD on hemodialysis.

查看原文本刊更多论文

血液透析患者的糖尿病和血糖管理。

糖尿病是终末期肾病（ESKD）的主要病因。在这一人群中，血糖管理具有挑战性，通常用于监测血糖控制的糖化血红蛋白是不可靠的。连续血糖监测指标可用于ESKD患者的血糖监测。二肽基肽酶4抑制剂、促肠促胰岛素模拟药物（胰高血糖素样肽1和葡萄糖依赖性胰岛素性肽受体激动剂）和使用自动胰岛素输送系统的胰岛素是治疗血液透析ESKD患者糖尿病的首选方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Spectrum Medicine-Internal Medicine

CiteScore

2.70

自引率

0.00%

发文量

期刊介绍： The mission of Diabetes Spectrum: From Research to Practice is to assist health care professionals in the development of strategies to individualize treatment and diabetes self-management education for improved quality of life and diabetes control. These goals are achieved by presenting review as well as original, peer-reviewed articles on topics in clinical diabetes management, professional and patient education, nutrition, behavioral science and counseling, educational program development, and advocacy. In each issue, the FROM RESEARCH TO PRACTICE section explores, in depth, a diabetes care topic and provides practical application of current research findings.